Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danicopan in C3G and IC-MPGN
NCT03124368Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Aug 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of danicopan in Complement 3 glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), sponsored by Alexion Pharmaceuticals. Started Aug 2017; status: completed.
02
Drugs
danicopan
03
Conditions
Complement 3 glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Beyond the preview
Go deeper on NCT03124368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03124368.